Câncer Anal

5-Fluorouracil + Mitomicina C
5-Fluorouracil: 1,000 mg/m²/dia IV por infusão contínua D1–4 e D29–32 concomitante a radioterapia  
Mitomicina C: 15 mg/m² IV no D1  
Ref. (1)

5-Fluorouracil + Mitomicina C
5-Fluorouracil: 750 mg/m²/dia IV infusão contínua D1-5 e D29–33, concomitante a radioterapia  
Mitomicina C: 15 mg/m² IV no D1  
Ref. (2)

5-Fluorouracil + Cisplatina
5-Fluorouracil: 1,000 mg/m²/dia IV infusão contínua nos D1 a 5  
Cisplatina: 75 mg/m² IV D2  
Ref. (3)

Capecitabina + Mitomicina C
Capecitabina: 825mg/m² VO BID durante os dias da radioterapia  
Mitomicina C: 12mg/m² IV D1  
Ref. (4)

2. Bartelink H, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization por Research e Treatment of


4. Glynne-Jones R; Meadows H; Wan S; Gollins S; Leslie M; Levine E; McDonald AC; Myint S; Samuel L; Sebag-Montefiore D. Multicenter Phase II Study of Chemoradiation Using a 5 Day per Week Oral Regimen of Capecitabine and Intravenous Mitomycin C in Anal Cancer. Int J Radiat Oncol Biol Phys. 2008 May 7.